Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure

Christopher Em Griffiths; Melinda Gooderham; Jean‐Frédéric Colombel; Tadashi Terui; Ana P. Accioly; Gaia Gallo; Danting Zhu; Andrew Blauvelt

doi:10.1007/s13555-022-00743-9

Abstract

1 min read

The long-term safety profile for ixekizumab is consistent with that previously reported in patients with psoriasis. No new or unexpected safety events were detected.

Related publications

Article2020

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp

Article2022

32236 Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: Data from 15 clinical trials with over 18,000 patient-years of exposure

Christopher Em Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel, Tadashi Terui, Ana P. Accioly, Gaia Gallo, Danting Zhu, Andrew Blauvelt

Article2025

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Mark Lebwohl, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Article2023

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths

Letter2023

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

April W. Armstrong, Kilian Eyerich, Curdin Conrad, Yihong Zhu, Ya‐Wen Yang, Megan Miller, Yin You, Yaung‐Kaung Shen, Peter Foley, Christopher Em Griffiths, Bruce Strober